Orbimed Advisors LLC Alx Oncology Holdings Inc Transaction History

Orbimed Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.84 - $17.56 $4.81 Million - $14.5 Million	-823,508 Reduced 30.3%	1,894,462 $11.4 Million
Q1 2024 May 15, 2024	SELL	$10.95 - $16.79 $4.13 Million - $6.33 Million	-377,030 Reduced 12.18%	2,717,970 $30.3 Million
Q4 2023 Feb 14, 2024	BUY	$4.81 - $15.38 $1.08 Million - $3.45 Million	224,000 Added 7.8%	3,095,000 $46.1 Million
Q3 2022 Nov 14, 2022	BUY	$8.23 - $15.14 $5.64 Million - $10.4 Million	684,731 Added 31.32%	2,871,000 $27.5 Million
Q2 2022 Aug 15, 2022	BUY	$5.89 - $19.46 $9.22 Million - $30.4 Million	1,564,569 Added 251.66%	2,186,269 $17.7 Million
Q1 2022 May 16, 2022	BUY	$13.65 - $22.06 $5.65 Million - $9.14 Million	414,100 Added 199.47%	621,700 $10.5 Million
Q4 2021 Feb 14, 2022	BUY	$21.49 - $74.4 $1.24 Million - $4.29 Million	57,600 Added 38.4%	207,600 $4.46 Million
Q4 2020 Feb 16, 2021	BUY	$34.11 - $112.26 $5.12 Million - $16.8 Million	150,000 New	150,000 $12.9 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $52.6M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.